Bulletin
Investor Alert

Market Pulse Archives

June 12, 2020, 8:21 a.m. EDT

Shares of Apellis rise on clinical data for rare blood disease drug

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Apellis Pharmaceuticals Inc. (APLS)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Apellis Pharmaceuticals Inc. /zigman2/quotes/202103251/composite APLS -4.21% gained 5.1% in premarket trading on Friday after it shared details from a late-stage clinical trial evaluating its experimental drug pegcetacoplan against Alexion Pharmaceuticals Inc.'s Soliris as a treatment for paroxysmal nocturnal hemoglobinuria. The study found that pegcetacoplan was better than Soliris in improving hemoglobin levels in adults with the rare blood disease. Soliris brought in $3.9 billion in revenue in 2019. Apellis said it plans to submit a new drug application for pegcetacoplan to the Food and Drug Administration in the second half of the year. Its stock is down 0.5% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.81% has declined 7.1%.

/zigman2/quotes/202103251/composite
US : U.S.: Nasdaq
$ 42.55
-1.87 -4.21%
Volume: 746,476
May 24, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.73 billion
Rev. per Employee
$170,050
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,941.48
-32.27 -0.81%
Volume: 2.44B
May 24, 2022 4:55p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.